NXL New Plan Excel Realty Trust, I
New Plan Excel Realty Trust, I Missed Consensus Estimates
New Plan Excel Realty Trust, I (NXL) reported a loss of $3.43 per share on revenue of $0.08 million for the third quarter ended September 2026. The consensus estimate was a loss of $2.91 per share on revenue of $0.08 million. The company missed consensus estimates by 17.87% while revenue grew 333.33% on a year-over-year basis.
Nexalin Technology Inc. designs and develops neurostimulation products for mental health epidemic. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. Nexalin Technology Inc. is based in Houston, Texas.
*Reported earnings and revenue figures shown above, and any guidance given, are preliminary and may be updated upon further review.*